Biocon Expects Stronger Fiscal 2027 Second Half on Biosimilar and Insulin Demand
Biocon expects performance in the second half of fiscal 2027 to exceed the first six months, citing US biosimilar sales, planned launches of pertuzumab in Europe and Brazil, and rising insulin demand.